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ABSTRACT: The aim of this study was to compare the health-related quality of life
(HRQL) of asthma patients treated according to the 1997 National Institute of Health
(NIH) international asthma guideline and that of asthmatics receiving non-guideline
treatment.
The suitability of 146 asthmatics9 medication regimes was determined according to
the 1997 NIH asthma guideline. Quality of life was assessed on a seven-point scale
using the Asthma Quality of Life questionnaire.
Just over half of the patients were not currently using the treatment considered
necessary for controlling their asthma. Patients treated according to the guideline
(n=72) had a significantly higher overall HRQL than patients with non-guideline
treatment (5.7 versus 5.3). The differences were also significant for the subscales
measuring symptoms and environmental exposure, but not for activities or emotional
function.
An association between non-guideline treatment and a poorer health-related quality
of life in asthma patients treated in general practice was observed. This study supports
the role of evidence-based guidelines in daily practice. Further studies are needed to
determine if guideline treatment is responsible for the increase in health-related quality
of life observed in this work.
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Asthma is a chronic inflammatory airway condition affect-
ingw8% of adults in Western Europe [1]. Like most chronic
conditions, the majority of asthma patients are managed in
general practice [2]. International consensus regarding opti-
mal treatment for asthma has existed since the early 1990s, as
evident in the international guidelines first published in 1992
[3]. These guidelines aimed to help healthcare professionals
bridge the gap between current knowledge and daily practice,
and to standardise and improve the quality of asthma care
provided. Over the past decade these guidelines have been
reviewed and updated [4], and at the time of the current study
in 1999/2000 the most recent international guideline was that
published in 1997 by the National Institute of Health (NIH)
[5]. Pharmacotherapy is an important element in the optimal
management of asthma as recommended in the guidelines.
Common to all versions of the guidelines, the goals of asthma
therapy are to improve the patient9s quality of life by
preventing chronic and troublesome symptoms, maintaining
"normal" lung function, maintaining normal activity levels,
preventing recurrent exacerbations and providing optimal
pharmacotherapy with minimal adverse effects.
While the goals of asthma therapy focus on the patient,
assessment of the guidelines and their effectiveness has
focused on physicians. Little attention has been given to the
effect of guidelines on patient outcomes, such as mortality,
morbidity or quality of life in asthma. Prescriber adherence to
the asthma guidelines with respect to diagnostic procedures,
drug therapy and patient self-management counselling has
been investigated [2, 6–8]. While explicit guidelines have been
shown to improve physician clinical practice, it is not known
if such improvement has similar positive effects on patient
outcomes [9, 10]. Earlier work on the effect of guidelines on
patient outcomes concluded that there was little evidence that
clinical guidelines are effective in improving patient outcomes,
although the poor quality of the guidelines investigated was
believed to have had a major influence on this finding
[11]. More recent work has indicated that asthma patients
receiving guideline-recommended drug therapies have less
hospital admissions [12, 13] and better lung function [14] than
patients not treated according to the guidelines. What remains
unknown is the effect of guidelines on the patient9s asthma-
related quality of life. In this study, health-related quality of
life (HRQL) in asthma patients managed in general practice
who are treated according to the NIH asthma guideline were




The Registratie Netwerk Groningen (RNG) is a general
practice database from the northern Netherlands. At the time
of the study, the RNG included 30,486 patients registered
with 16 general practitioners (GP)s. All participating GPs use
the database in place of paper medical records.
All patients were aged 18–49 yrs with an anti-asthma medi-
cation (Anatomical Therapeutic Chemical classification group
R03 [15]) or an asthma contact (International Classification
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of primary Care code R96 [16]) during 1997. Data from 1997
was used for recruitment to ensure that patients had chronic
asthma. Patients no longer registered with an RNG doctor or
receiving anti-asthma medications for nonasthma indications
were ineligible. GPs invited eligible patients to attend a
clinical appointment with a research assistant. A reminder
letter was sent to nonrespondents within 3 months of the
initial invitation. Anonymous age and sex, and prescribing
data for nonresponding patients was obtained from the
database to enable comparison between nonresponders and
patients participating in the study. The local medical ethics
committee approved the study and informed consent was
obtained from each participant.
Methods
Participating patients attended a single research appoint-
ment (May–December 2000) where forced expiratory volume
in one second (FEV1) was measured and a questionnaire
regarding recent asthma symptoms, medication use and
asthma-related quality of life was completed by each
participant. FEV1 was assessed by an experienced research
assistant trained in spirometry according to the standards of
the American Thoracic Society using a Microlab 3300
spirometer (Micro Medical Ltd, Rochester, UK). For each
participant the best of three readings was used.
Definition of guideline adherence
Each patient9s treatment regime, as obtained from the
interviews, was classified as adherent or nonadherent using an
algorithm based on the recommendations from the NIH
Expert Panel Report 2 Guidelines for the Diagnosis and
Management of Asthma [5]. Adherence to the guideline was
defined as any drug or drug combination recommended in
this international asthma guideline for the relevant asthma
severity (table 1). Since improving lung function and reducing
symptoms are important treatment aims, drug combinations
from higher asthma severity classifications were also con-
sidered adherent for patients with a lower severity classifica-
tion.
Self-reported medication use by patient interview has been
shown to be a reliable method of obtaining information
regarding current medication use [17, 18]. Accuracy of self-
reported medication use was further improved by having
patients bring all their current asthma medications to the
clinical appointment. The research assistant also questioned
patients during the clinical appointment about their current
asthma medications, using both brand and generic names.
Since there is no objective severity classification for treated
asthma patients, the severity classification from the interna-
tional NIH guideline for pharmacological management of
asthma was used [5]. This classification uses a combination of
symptoms and lung function to determine asthma severity
rather than relying on a single component. In accordance with
these NIH criteria (table 1), questions referring to the
frequency of night-time symptoms (less than twice a month,
more than twice a month, once a week, more than once a
week) and day-time symptoms requiring bronchodilator use
(0–3 days per week, 3–6 days per week, 1–2 times per day, o3
times per day) were used in combination with the FEV1 as
assessed at the research appointment to classify the patients.
Patients were assigned to the most severe grade in which a
feature occurs. For example, a patient with night-time symp-
toms less than twice a month, but symptoms once to twice a
day, and a FEV1 of 70% was assigned in class 3.
Table 1. – Severity classification and treatment recommendation for the 1997 National Institute of Health asthma guideline
Severity classification# Medication recommendations
Class 1 Symptoms: ftwice a week Inhaled SABA when needed
Asymptomatic and normal PEF between Salbutamol 100–400 mg or
exacerbations Terbutaline 250–500 mg or
Exacerbations brief Fenoterol 200 mg
Night time symptoms: twice a month
Lung function: FEV1 or PEF o80% pred
Class 2 Symptoms:wtwice a week butvonce a day Inhaled SABA and ICS
Exacerbations may affect activity Beclomethasone/budesonide 200–400 mg or
Night time symptoms:wtwice a month Fluticasone 100–250 mg twice daily
Lung function: FEV1 or PEF o80% pred Cromoglycate 5–10 mg four times daily may replace
ICS
Class 3 Symptoms: daily Inhaled SABA and ICS
Daily inhaled SABA use Beclomethasone/budesonide 800 mg or
Exacerbations affect activity Fluticasone 500 mg twice daily
Exacerbations: o twice a week or
Night time symptoms:wonce a week Inhaled SABA and ICS and inhaled LABA
Lung function: FEV1 or PEFw60% and
v80% pred
ICS: beclomethasone/budesonide 400 mg or
Fluticasone 250 mg twice daily
LABA: salmeterol 50–100 mg or
Formoterol 6–24 mg twice daily
Class 4 Symptoms: continual SABA and high-dose ICS and LABA and/or
Limited physical activity ipratropium
Frequent exacerbations ICS: beclomethasone/budesonide 800 mg or
Fluticasone 500 mg twice dailyNight time symptoms: frequent
Lung function: FEV1 or PEF f60% pred LABA: salmeterol 50–100 mg or
Formoterol 6–24 mg twice daily
Ipratropium 20–40 mg
PEF: peak expiratory flow; FEV1: forced expiratory volume in one second; % pred: % predicted; SABA: short-acting b-agonists; ICS: inhaled
corticosteroids; LABA: long-acting b-agonists. #: the presence of one or more of the features of severity is sufficient to place a patient in that
category; an individual should be assigned to the most severe grade in which any feature occurs.
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Health-related quality of life assessment
HRQL was assessed using the Adult Asthma Quality of
Life Questionnaire (AQLQ) [19]. The AQLQ is a validated
disease-specific quality of life questionnaire consisting of 32
items measuring four domains of asthma-related health: 12
items assess symptoms, five measure emotional function, four
assess exposure to environmental stimuli and 11 determine
activity limitations due to asthma. The AQLQ uses a seven-
point scale where a higher score corresponds to a better
HRQL. Each participant completed the self-administered,
Dutch language version of this instrument during the research
appointment.
Sample size
In earlier studies using the AQLQ, the mean score for
asthma patients treated in general practice ranged 4.6–6.0
[20]. In order to detect a difference in HRQL of 0.5, o63
patients with adherent and 63 with nonadherent treatment
regimes were required. Previous work clinically assessing
asthma treatment found the proportion of patients with
pharmacotherapy not adherent to that recommended in the
guidelines to bey60% [2, 7]. Thus, the study aimed to recruit
160 patients in order to achieve a power of 0.80 with an alpha
of 0.05.
Analysis
An unpaired t-test was used to assess the difference in
overall HRQL and in scores on the four subscales between




In total, 369 eligible patients were invited to attend a
clinical appointment, of which 152 patients were willing to
participate. After initial contact by the researchers, six
patients were unable to attend an interview during the study
period, leaving a final study population of 146 (response rate
39.6%). There was no significant difference with respect to sex
(58.2 and 57.8% female, respectively) between participating
patients (n=146) and nonrespondents (n=223). Participating
patients were slightly older (aged 39.8 versus 35.8 yrs,
pv0.05). There were no significant differences between parti-
cipating and nonresponding patients in the mean volume
prescribed per patient for inhaled short-acting b-agonists,
inhaled corticosteroids, inhaled anticholinergics and oral
salbutamol.
Medication use
Patients9 severity classification and current asthma medica-
tion use are shown in table 2. Six patients (4.1%) reported
using no current asthma medications. Of the 38 patients not
using a short-acting b-agonist, six were using ipratropium,
11 a long-acting b-agonist, and two were using both.
Salbutamol was the most commonly used short-acting b-
agonist used by 88.2% (90/102) of patients reporting use of
a short-acting b-agonist. Of the remaining short-acting
b-agonist users 12 used terbutaline and one each rimiterol
and fenoterol. One patient was using both salbutamol and
terbutaline, and one patient salbutamol and rimiterol.
The most commonly used inhaled corticosteroid was
budesonide (59/95, 62.1%). Twenty-two patients used beclo-
methasone and 14 patients fluticasone. Long-acting b-agonists
were used by 22 patients. Salmeterol was used by 13 patients
and formoterol by nine patients. While 70% of patients were
using an inhaled short-acting b-agonist and 65% of patients
an inhaled corticosteroid, only 42.% (62/146) used an inhaled
short-acting b-agonist and an inhaled corticosteroid.
Non-guideline treatment regimes
Just over half of the treatment regimes were considered as
nonadherent to guideline recommendations (table 2). Of the
14 patients in severity class 1 not using a short-acting
b-agonist, none were using ipratropium and two were using
a long-acting b-agonist. The majority of these patients (n=12)
were using inhaled corticosteroids.
The main reason for nonadherent therapy among class 2
patients (n=5) was the lack of anti-inflammatory treatment
(n=4). One patient was using anti-inflammatory treatment and
a long-acting b-agonist.
Lack of anti-inflammatory treatment was also a major
factor contributing to nonadherent treatment for patients in
asthma severity class 3. Of the 40 patients with a treatment
regime not recommended in the guideline, 27 were not
currently using any anti-inflammatory medication and one
was using cromoglycate in place of the inhaled corticosteroid
recommended in the guideline. Eighteen class 3 patients were
not using a short-acting b-agonist. From these 18, five were
using ipratropium, four a long-acting b-agonist and one was
using both. There were six patients in this severity class with
neither a short-acting b-agonist nor an inhaled corticosteroid.
In severity class 4, the most severe class, there were 13
patients without a guideline-recommended treatment regime.
Of the ten patients with no short-acting b-agonist, one had
ipratropium, five a long-acting b-agonist and one had both.
Table 2. – Patients9 classification of severity and medication regimes
Class 1 Class 2 Class 3 Class 4 Total
Total 51 9 70 16 146
Adherent regimes 35# (69) 4 (44) 30 (43) 3 (19) 72
Nonadherent regimes 74
No current medication 2 (4) 0 4 (6) 0
No short-acting b-agonist 14 (27) 1 (11) 14 (20) 9 (56)
Only short-acting b-agonist 4 (44) 19 (27) 2 (13)
Other regimes lacking inhaled corticosteroid 0 3 (4) 1 (6)
Other regimes lacking long-acting b-agonist 1 (6)
Data are presented as n (%). #: including nine with only a short acting b-agonist.
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Three patients had no anti-inflammatory medication and one
was using cromoglycate in place of an inhaled corticosteroid.
There were six patients without either a long-acting b-agonist
or ipratropium.
Health-related quality of life
For the total patient population, the mean HRQL was
5.5¡1.0. The HRQL was observed to decrease as asthma
severity increased from 6.1¡0.7 for patients in severity class 1,
5.5¡0.4 for severity class 2, 5.2¡0.9 for severity class 3 and
4.8¡1.2 for severity class 4.
As seen in table 3, asthma patients treated according to the
guideline had a significantly higher HRQL than those with
non-guideline regimes (5.7 versus 5.3, pv0.01). For all four
subscales, there was a positive difference for patients treated
according to the guideline, which was significant for the
domains "symptoms" and "environmental exposure".
Discussion
A number of treatment patterns not in accordance to the
recommendations in the NIH guideline were found. More
than half of the patients participating in this study were not
currently using the treatment considered necessary for
controlling their asthma. Around a third of patients were
not using any short-acting b-agonist. Disturbingly, this
proportion was even higher in patients classified in severity
class 4. A small number of such patients were using
ipratropium, which although not recommended in the guide-
line as a bronchodilator, has traditionally been used in this
role. A larger number of patients without a short-acting
b-agonist were using a long-acting b-agonist. While the
pharmacokinetics of formoterol may support its use as a
bronchodilator, the majority of patients in this study were
using salmeterol. Salmeterol does not share the same
pharmacokinetic profile as formoterol and may not be
suitable for rapid relief of symptoms in an acute situation.
Under use of inhaled corticosteroids was also evident in the
study population. Whether these patients had ever been
prescribed a corticosteroid is not known and further
investigation is needed to discover if this is a prescriber or
patient problem. Similar patterns of poor use of preventive
medication and lack of prescribed rescue medication have
been identified in other studies, and were found to be
associated with an increased risk of hospitalisation [12, 13].
The current study showed that asthma patients treated
according to the NIH guideline also have a significantly better
HRQL than patients not treated according to this guideline,
especially in terms of symptoms and environmental exposure.
It has been argued that clinical relevance of differences in
quality of life is of more importance to the prescriber than
statistical significance [21]. A difference of 0.5 points on the
AQLQ has been determined to represent a clinically relevant
difference for measuring change within a single patient
allowing for individual variation [22]. However, AQLQ
scores were compared between two patient groups where it
can be expected that the individual variation within the two
groups should be similar and a smaller difference could be
considered clinically relevant. Thus the differences observed
of 0.4 points in overall HRQL, as well as in the symptoms
subscale, and of 0.6 points in the environmental exposure
subscale are not only statistically significant but also border-
line clinically relevant. Non-guideline treatment seems to have
the least effect on emotional function of the asthma patients,
which is in line with other studies in which the treatment
regime appeared to have more impact on symptoms and
environmental exposure than on emotional function [23].
In general, the HRQL among the patients participating in
the study (mean 5.5) was relatively high. Other studies have
also found that the average HRQL in mild-to-moderate
asthma patients is close to that of the general population [24].
A strong link between asthma-related quality of life and
disease severity has been reported [20, 25], and this relation-
ship was also observed in the current study. For all patients,
irrespective of their treatment, the HRQL decreased from 6.1
for severity class 1 patients to 4.8 for the most severe patients,
which is similar to that seen in other studies [20]. It is most
likely that the relationship between HRQL and asthma
severity is due to the relationship between HRQL and
asthma symptoms [26, 27].
Since no objective severity classification for treated asthma
patients exists, the severity classification presented in the NIH
guideline was used in the current study [5]. This classification
uses a combination of day-time and night-time symptoms,
need for inhaled short-acting b-agonist and lung function to
determine asthma severity. It is often used to categorise
patients in research, but may underestimate actual severity in
patients that are well controlled with treatment [28]. In a first
attempt to validate the assessment of asthma severity in
patients mostly taking treatment, it was concluded that the
severity classification recommended by clinical guidelines,
such as the NIH, is useful for clinical assessment and
management of asthma patients in general practice [29]. In
the current study, a possible underestimation of severity does
not affect the assessment on whether the treatment is adherent
to the guideline, because treatment recommendations follow a
step-wise progression. Treatment for a higher severity is
always in addition to treatment from a lower severity either
with respect to increasing the dose of an existing medication
or the addition of a new medication. Thus, adequate
treatment according to the guideline for a particular severity
class implies that the treatment will also be considered
adequate for a lower severity class.
While the response rate in this study was rather low (40%),
sufficient numbers of patients with adherent and with non-
adherent treatment regimes were recruited. There were no
large differences between participants and nonrespondents in
terms of age, sex or prescribed medication. The low response
rate may be related to the age group targeted (18–49 yrs), since
this group comprises a large proportion of the workforce and
Table 3. – Health-related quality of life scores (HRQL) measured on seven-point scales
All asthma patients Adherent medication regime Nonadherent medication regime p-value#
Activities 5.4¡1.1 5.5¡1.0 5.2¡1.1 0.079
Symptoms 5.5¡1.1 5.7¡1.0 5.3¡1.1 0.047
Emotional function 6.0¡1.0 6.1¡0.9 5.9¡1.1 0.347
Environmental exposure 5.3¡1.2 5.6¡1.0 5.0¡1.3 0.002
Overall HRQL 5.5¡0.9 5.7¡0.8 5.3¡1.0 0.008
Data are presented as mean¡SD. #: testing for difference between adherent and nonadherent regimes.
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may be less willing to attend the research appointment.
To determine the patients9 current asthma medication
regime, each patient was questioned about their asthma
medications using both brand and generic names, as well as
having each patient bring their current medications along to
the clinical appointment. The method focuses on what the
patient is currently using, either daily or as needed, and not
necessarily on what the doctor has prescribed. It has been
reported that specific patient groups do not redeem as many
as 27% of prescriptions [30], thus a doctor may have pre-
scribed a guideline-based regime that a patient has chosen not
to have dispensed. This indicates that from a GP9s perspective
this study may underestimate the proportion of patients being
prescribed medication according to the guidelines.
In conclusion, a significant proportion of non-guideline
treatment in asthma patients in general practice was observed,
which was associated with a poorer health-related quality of
life. Further studies are needed to determine if treatment
adhering to that recommended in the guidelines is responsible
for the better asthma-related quality of life observed in this
work. For doctors and other healthcare professionals this
study emphasises the relevance of using evidence-based
treatment guidelines in daily medical practice.
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